HK1017845A1 - Aerosol compositions. - Google Patents

Aerosol compositions.

Info

Publication number
HK1017845A1
HK1017845A1 HK99102062A HK99102062A HK1017845A1 HK 1017845 A1 HK1017845 A1 HK 1017845A1 HK 99102062 A HK99102062 A HK 99102062A HK 99102062 A HK99102062 A HK 99102062A HK 1017845 A1 HK1017845 A1 HK 1017845A1
Authority
HK
Hong Kong
Prior art keywords
liquefied hydrofluoroalkane
fatty acid
active ingredient
medium
chain fatty
Prior art date
Application number
HK99102062A
Other languages
English (en)
Inventor
Saburo Murata
Fumio Shimojo
Yuji Tokunaga
Takehisa Hata
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of HK1017845A1 publication Critical patent/HK1017845A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HK99102062A 1995-09-19 1999-05-07 Aerosol compositions. HK1017845A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23934295 1995-09-19
PCT/JP1996/002670 WO1997010806A1 (en) 1995-09-19 1996-09-18 Aerosol compositions

Publications (1)

Publication Number Publication Date
HK1017845A1 true HK1017845A1 (en) 1999-12-03

Family

ID=17043318

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99102062A HK1017845A1 (en) 1995-09-19 1999-05-07 Aerosol compositions.

Country Status (16)

Country Link
US (2) US6361760B1 (da)
EP (1) EP0851753B1 (da)
JP (2) JP3362394B2 (da)
KR (1) KR100523754B1 (da)
CN (1) CN1137680C (da)
AT (1) ATE254450T1 (da)
AU (1) AU719613B2 (da)
CA (1) CA2232378C (da)
DE (1) DE69630798T2 (da)
DK (1) DK0851753T3 (da)
ES (1) ES2206590T3 (da)
HK (1) HK1017845A1 (da)
PT (1) PT851753E (da)
TW (1) TW429153B (da)
WO (1) WO1997010806A1 (da)
ZA (1) ZA967887B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284226B1 (en) * 1997-03-14 2001-09-04 Fujisawa Pharmaceutical Co., Ltd. Aerosol composition containing middle-chain fatty acid triglyceride dispersant
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
WO2003102151A2 (en) * 2002-05-30 2003-12-11 Celgene Corporation Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
AU2002952559A0 (en) * 2002-11-08 2002-11-21 Fujisawa Pharmaceutical Co., Ltd. New use
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US20040230272A1 (en) * 2003-04-11 2004-11-18 Cates Adam W. Subcutaneous lead with temporary pharmacological agents
BRPI0411385A (pt) * 2003-06-10 2006-08-29 Astellas Pharma Inc preparação em aerossol compreendendo um invólucro que encerra uma composição em aerossol contendo um composto de macrolìdeo
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
CN1901903A (zh) * 2003-11-06 2007-01-24 细胞基因公司 用于治疗和控制石棉相关性疾病和病症的包含jnk抑制剂的组合物以及其使用方法
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JP2007516951A (ja) * 2003-12-30 2007-06-28 アステラス製薬株式会社 気道閉塞症の治療または予防のためのマクロライドの使用
MX2007006066A (es) * 2004-11-23 2007-07-11 Celgene Corp Inhibidores de jnk para el tratamiento de lesiones del snc.
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0608152A2 (pt) * 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
CN103127100A (zh) * 2006-03-23 2013-06-05 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂和方法
JP5959795B2 (ja) 2006-08-18 2016-08-02 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 血液脳関門送達のための物質
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
EP2362766A2 (en) * 2008-11-04 2011-09-07 Cipla Limited Pharmaceutical aerosol composition
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
ES2533536T3 (es) 2009-11-19 2015-04-10 Solis Biodyne Oü Composiciones para aumentar la estabilidad y actividad de polipéptidos, y métodos relacionados
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
CA2857647C (en) 2011-12-02 2022-04-19 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
JP6692293B2 (ja) 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおける酵素活性を増大するための方法および組成物
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
IE66485B1 (en) 1989-07-05 1996-01-10 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
PH31204A (en) 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
DK0669127T3 (da) 1992-11-18 1999-12-06 Fujisawa Pharmaceutical Co Farmaceutisk præparat med forlænget virkning
JPH06345646A (ja) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US5681501A (en) * 1995-10-11 1997-10-28 E. I. Du Pont De Nemours And Company Compositions including a hydrofluoropropane
US6284226B1 (en) * 1997-03-14 2001-09-04 Fujisawa Pharmaceutical Co., Ltd. Aerosol composition containing middle-chain fatty acid triglyceride dispersant
WO1998046268A1 (fr) 1997-04-11 1998-10-22 Fujisawa Pharmaceutical Co., Ltd. Composition medicamenteuse

Also Published As

Publication number Publication date
US6524556B2 (en) 2003-02-25
US6361760B1 (en) 2002-03-26
WO1997010806A1 (en) 1997-03-27
DK0851753T3 (da) 2004-03-15
JP3266005B2 (ja) 2002-03-18
DE69630798T2 (de) 2004-09-23
TW429153B (en) 2001-04-11
CN1137680C (zh) 2004-02-11
KR100523754B1 (ko) 2007-06-04
JPH09143054A (ja) 1997-06-03
PT851753E (pt) 2004-04-30
ATE254450T1 (de) 2003-12-15
ZA967887B (en) 1997-04-07
EP0851753A1 (en) 1998-07-08
AU719613B2 (en) 2000-05-11
EP0851753B1 (en) 2003-11-19
JP3362394B2 (ja) 2003-01-07
CA2232378A1 (en) 1997-03-27
AU6999896A (en) 1997-04-09
KR19990044656A (ko) 1999-06-25
JP2000505050A (ja) 2000-04-25
CA2232378C (en) 2009-04-14
US20020061906A1 (en) 2002-05-23
CN1201384A (zh) 1998-12-09
DE69630798D1 (de) 2003-12-24
ES2206590T3 (es) 2004-05-16

Similar Documents

Publication Publication Date Title
TW429153B (en) Aerosol compositions
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
GB2062465B (en) Topical preparation containing nitroglycerine and optionally other medicaments
CA2105575A1 (en) Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
NZ330369A (en) aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester
NZ308293A (en) Antibacterial-wound healing compositions comprising a pyruvate, antioxidant and fatty acids
MY119074A (en) Pharmaceutical aerosol composition
MX9606502A (es) Composiciones antiqueratoliticas y curativas para heridas y metodos para preparar y utilizar las mismas.
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.
JPS5659710A (en) Preventive and remedy for psoriasis
EP0147535A3 (en) Pharmaceutical composition comprising an e-type prostaglandin compound and useful as a topical medicament
AU1112395A (en) Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide
AU3271795A (en) Synergistic pharmaceutical compositions containing triamcinolone acetonide and halcinonide
EP0968713A4 (en) PATCHES CONTAINING ISOSORBID NITRATE
AU8740198A (en) Inhibitor and preservative formulation
EP0966958A4 (en) AEROSOL PREPARATION
MY105086A (en) Liquid detergent composition.
ES456094A1 (es) Un procedimiento para la preparacion de 2-acetoxi-benzoato de 2-(carbamoil) fenilo.
AU528211B2 (en) Synergistic analgesic compositions of suprofen
LT2001072A (lt) Maisto papildas
CA2066945A1 (en) Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
AU2989701A (en) Pharmaceutical carrier composition for papayne based products

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080918